

Most of the published information about PIE has been shared only during conferences and mostly authored by consultancies

Similar to the trend noted in an earlier literature review,¹ most of the published information about PIE from 2023-2025 has been shared only during conferences and mostly authored by consultancies (**Table 1**).

Of the 14 sources identified for inclusion, 12 were conference proceedings (85.7%). Overall, 100% (14 of 14) of the studies contained authors from consultancies and 7.1% (1 of 14) involved authors from manufacturers. All of the studies reported outcomes for healthcare decision makers (100%; 14 of 14); none reported outcomes for manufacturers (0%; 0 of 14).

Table 1. PIE-related Publications from January 2023 to December 2025

Author	Author affiliation	Article type	Study type	Data sources	Survey date
Dodda 2023 ²	Xcenda	Journal article	Review article and web-based survey	Market research panel of HCDMs who were registered users of FormularyDecisions (N=23)	2021
Farahbakhshian 2023 ³	Xcenda, Takeda	Abstract only	Online survey	HCDMs (N=22); details NR	NR
Bannister 2023 ⁴	Lumarity, Inc.	Abstract only	Quantitative survey	HCDMs (N=62); details NR	Jun 2023
Brisibe 2024 ⁵	Cencora	Journal article	Double-blind, web-based survey	Research panel of HCDMs who were registered users of FormularyDecisions (N=17)	May 2022
Noonan 2024 ⁶	Cencora	Poster	Double-blind, web-based survey	HCDMs from Cencora's Managed Care Network (N=32)	Sep 2023
Maliqi 2024 ⁷	Cencora	Poster	A double-blinded, web-based survey	HCDMs from Cencora's Managed Care Network (N=45)	Jun-23
Penley 2024c ⁸	Cencora	Poster			
Penley 2024a ⁹	Cencora	Poster	Web-based survey	HCDMs from Cencora's Managed Care Network (N=41)	May 2024
Penley 2024b ^{*10}	Cencora	Poster			
Lodowski 2024 ¹¹	Petuari	Poster	Online quantitative and qualitative survey	HCDMs from Petuari Payer Network (N=20)	May 2024
Yoshida 2025 ¹²	Cencora	Abstract only	Web-based survey	HCDMs from Cencora's Managed Care Network (N=10)	Feb 2025
Streeton 2025a ¹³	Petauri	Poster	Online quantitative and qualitative survey	HCDMs recruited from Petuari Payer Network (N=18)	Mar 2025
Streeton 2025b ¹⁴	Petauri Evidence	Poster			
Penley 2025 ¹⁵	Cencora	Abstract only	Double-blind, web-based survey	HCDMs who were registered users of FormularyDecisions (N=31)	April 2025

* This poster was also presented at the 2025 National Association of Specialty Pharmacy conference, but it is only counted as one publication.

HCDM = healthcare decision maker; NR = not reported

References

1. Smith D. HPR52 Pre-Approval Information Exchange (PIE) in the US. Sharing the Pie. *Value in Health*. 01 Jun 2023;26(6 Suppl.):S220.
2. Dodda S, Bannister B, Hydery T, Gorey C, Dunlap S, Mody L. Best practices in designing preapproval information engagements for US health care decision makers. *J Manag Care Spec Pharm*. Mar 2023;29(3):245-250.
3. Farahbakhshian S, Arnold A, Liu E, et al. Understanding payer perceptions of preapproval information exchange in rare disease. *J Manag Care Spec Pharm*. 2023;29(3-a Suppl.):S106.
4. Bannister B, Sudol V, Lee J. Digital therapeutics coverage and reimbursement evidence expectations among US payers. *J Manag Care Spec Pharm*. 01 Oct 2023;29(10-a Suppl.):S115-S116.
5. Brisibe T, Hikmat Z, Hydery T, Gorey C, Boswell K. Health care decision-maker perceptions and trends in the utilization of preapproval information for formulary decision-making. *J Manag Care Spec Pharm*. May 2024;30(5):475-479.
6. Noonan K, Baker L, Schroader B, Hanna D, Abdel-Sattar M, Dale J. Payer perspectives of cell therapy and gene therapy treatment paradigms for an inherited retinal disorder. *J Manag Care Spec Pharm*. 01 Apr 2024;30(4-a Suppl.):S103.
7. Maliqi A, Penley B, Young N, Dragovich C. Early implementation of PIE for specific drug categories. *J Manag Care Spec Pharm*. 01 Apr 2024;30(4-a Suppl.):S98.
8. Penley B, Maliqi A, Young N, Dragovich C. Mind the "preapproval" gap: Payer preapproval information needs and how manufacturers can better meet them. *J Manag Care Spec Pharm*. 01 Apr 2024;30(4-a Suppl.):S105.
9. Penley B, Brisibe T, Dragovich C. How does preapproval information exchange affect formulary decision-making? *J Manag Care Spec Pharm*. 01 Oct 2024;30(10-c Suppl.):S128-S129.
10. Penley B, Hydery T, Dragovich C. Optimizing the timing of preapproval information exchange for oncology products, products for rare diseases, and cell and gene therapies. *J Manag Care Spec Pharm*. 01 Oct 2024;30(10-c Suppl.):S129-S130.
11. Lodowski N, Nordyke R, Tindall B, Coriale E, Honcz J, Chava SM. HPR31 Payer Preferences Around Manufacturer Provided Evidence and Engagements in the US. *Value in Health*. 01 Dec 2024;27(12 Suppl.):S281.
12. Yoshida S, Padwal T. Managed care insights on optimizing coverage coordination for therapies spanning medical and pharmacy benefits. Conference Abstract. *J Manag Care Spec Pharm*. 2025;31:S14.
13. Streeton S, Lodowski N. HTA16 AMCP Dossier v5.0: U.S. Payer Preferences and Utilization to Support Formulary Decision Making. *Value in Health*. 2025;28(6):S250.
14. Streeton SE, Lodowski N, Menon S, Maddison L. HTA348 US PIE and AMCP Dossiers: Payer Preferences Best Practice and a Comparison With Global Evidence Dossiers. *Value in Health*. 01 Dec 2025;28(12 Suppl. 1):S474.
15. Penley B, Hydery T, Gaiser A, Boswell K. Healthcare decision-maker insights on Academy of Managed Care Pharmacy Format Version 5.0 formulary dossiers. Conference Abstract. *J Manag Care Spec Pharm*. 2025;31.